About Wincal Bio

Wincal Biopharm (WincalBio) is focused on developing vascular therapeutics.  Our focused areas are 1) developing eyedrop formulations for therapeutic antibodies using proprietary Ocular Penetration Carrier (OPC) screening platform to identify a matching antibody:carrier pair that allows therapeutic antibodies reach intraocular space including aqueous chamber, vitreous, retina and choroid, which is difficult without injection. This non-invasive eyedrop delivery of therapeutic antibodies without intravitreal injections opens up broader treatment opportunities for multiple intraocular diseases including wet AMD, DME, diabetic retinopathy, uveitis, geographic atrophy, thyroid eye disease and uveal melanoma to lower the treatment burden for both patients and clinicians.  It can be used as a monotherapy with FDA approved anti-VEGF antibodies as well as combination with other novel target antibodies including cytokine targets such as ILs (IL-4, IL-6, IL-10, IL-17, IL-23), TNFa, TGFb, FGF, PEDF, FasL, EGFR as well as ocular cancer targets (PD-1, PD-L1, CTLA4). 2) Developing Next-Gen anti-VEGF therapeutics for ocular disease indications.  Novel tri-specific therapeutics are also being developed  for expanded indications with a single treatment option. Our lead program with preclinical  efficacy demonstration in mouse CNV model plans to initiate clinical studies in 2027 followed by other novel target programs. At Wincal Biopharm,  our commitment to in vivo science with a needle free  delivery as well as trispecific antibodies underpins to improve patient’s quality of life and compliance.